These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27811184)

  • 1. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.
    Zhang G; Scarborough H; Kim J; Rozhok AI; Chen YA; Zhang X; Song L; Bai Y; Fang B; Liu RZ; Koomen J; Tan AC; Degregori J; Haura EB
    Sci Signal; 2016 Oct; 9(450):rs12. PubMed ID: 27811184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
    Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
    Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
    Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S
    Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
    Heuckmann JM; Hölzel M; Sos ML; Heynck S; Balke-Want H; Koker M; Peifer M; Weiss J; Lovly CM; Grütter C; Rauh D; Pao W; Thomas RK
    Clin Cancer Res; 2011 Dec; 17(23):7394-401. PubMed ID: 21948233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405).
    Isozaki H; Hotta K; Ichihara E; Takigawa N; Ohashi K; Kubo T; Ninomiya T; Ninomiya K; Oda N; Yoshioka H; Ichikawa H; Inoue M; Takata I; Shibayama T; Kuyama S; Sugimoto K; Harada D; Harita S; Sendo T; Tanimoto M; Kiura K
    Clin Lung Cancer; 2016 Nov; 17(6):602-605. PubMed ID: 27405684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
    Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
    Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
    Lin YT; Yu CJ; Yang JC; Shih JY
    Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
    Tani T; Yasuda H; Hamamoto J; Kuroda A; Arai D; Ishioka K; Ohgino K; Miyawaki M; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
    Mol Cancer Ther; 2016 Jan; 15(1):162-71. PubMed ID: 26682573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
    Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
    Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
    Perez CA; Velez M; Raez LE; Santos ES
    Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.